It’s all assumptions but my thoughts are backed

It’s all assumptions but my thoughts are backed up by a couple other posters thoughts I have seen post in the past. CYDY trial for the better part of 80% of enrollment was at the bottom of hospitals list due to being small unknown company with a yet to be approved drug with no lobbyist. I believe that our drug was used most on critical patients and the most severe based on criteria above doctors and hospitals were most likely sending patients that had Best chance at survival to the big pharma trials that were listed above CYDY’s and more well known companies with already approved drugs that were repurposed for covid-19. I also believe that Leronlimab would help both stages whether it’s severe of critical. Main difference is critical had more immediate threat of death and severe from progressing to critical or death. I don’t think there’s any chance that overall mortality closer to 28% mark rather than actually being higher like 32% with an overall mortality closer to 22% I think we will see a very significant mortality reduction in leronlimab arm of trial vs placebo. I’ve heard people on both sides of the fence of whether data is unblinded or not yet. I believe data must be unblinded and in hands of fda now and many things going on behind the scene. I don’t think they would PR that data has unblinded. I also think the last communications we got several weeks ago were done right before unblinding but Nadar must have gotten update from Amarex of couple days out and possibly viewed it as last chance to update before getting very busy behind the scenes. All IMO but I can’t help the positive thoughts I have about CYDY and leronlimab. If 2-3 other drugs were approved already to reduce mortality I may be a little worried the fact that CYDY literally last one standing makes me feel confident FDA has to do right thing.